Skip to content

Study · Animal study (in vivo) · rat · 2011

7 results

Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.

Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS

British journal of pharmacology1 Nov 2011Cited by 75 (Europe PMC)

PMID21323903 (opens in a new tab)PMCIDPMC3221096 (opens in a new tab)DOI10.1111/j.1476-5381.2011.01272.x (opens in a new tab)PepBankPUB-21323903
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, exendin‑4 reduced the increase in current perception threshold at 2000 Hz.

    In plain wordsIn diabetic rats, exendin‑4 reduced the rise in nerve current perception threshold at 2000 Hz compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCurrent perception threshold at 2000 Hz
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    After exendin-4 treatment, the increase seen in current perception threshold values at 2000 and 250 Hz in diabetic rats was reduced.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, exendin‑4 reduced the increase in current perception threshold at 250 Hz.

    In plain wordsIn diabetic rats, exendin‑4 reduced the rise in nerve current perception threshold at 250 Hz compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCurrent perception threshold at 250 Hz
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    After exendin-4 treatment, the increase seen in current perception threshold values at 2000 and 250 Hz in diabetic rats was reduced.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, exendin‑4 ameliorated the decrease in sciatic nerve myelinated fibre size.

    In plain wordsIn diabetic rats, exendin‑4 reduced the loss of myelinated nerve fibre size compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMyelinated fibre size
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    Also, the decrease in myelinated fibre size or axon/fibre area ratio in the sciatic nerve and the loss of intraepidermal nerve fibre in the skin of diabetic rats were ameliorated.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, exendin‑4 ameliorated the decrease in sciatic nerve axon/fibre area ratio.

    In plain wordsIn diabetic rats, exendin‑4 reduced the decline in the axon-to-fibre area ratio compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAxon/fibre area ratio
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    Also, the decrease in myelinated fibre size or axon/fibre area ratio in the sciatic nerve and the loss of intraepidermal nerve fibre in the skin of diabetic rats were ameliorated.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, exendin‑4 ameliorated skin intraepidermal nerve fibre loss.

    In plain wordsIn diabetic rats, exendin‑4 reduced nerve fibre loss in the skin compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIntraepidermal nerve fibre loss
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    Also, the decrease in myelinated fibre size or axon/fibre area ratio in the sciatic nerve and the loss of intraepidermal nerve fibre in the skin of diabetic rats were ameliorated.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, exendin‑4 attenuated Schwann cell apoptosis compared with placebo.

    In plain wordsIn diabetic rats, exendin‑4 reduced Schwann cell death compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSchwann cell apoptosis
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    These responses were closely associated with the attenuation of Schwann cell apoptosis and improvement in the cAMP level in exendin-4-treated diabetic rats, compared with placebo-treated animals.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, exendin‑4 improved cAMP levels compared with placebo.

    In plain wordsIn diabetic rats, exendin‑4 improved cAMP levels compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasecAMP level
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic rats
    Comparator
    Placebo-treated diabetic rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1 nmol/kg/day · intraperitoneal · 24 weeksAs given in this study (rat).

    Source sentences

    Summary
    These responses were closely associated with the attenuation of Schwann cell apoptosis and improvement in the cAMP level in exendin-4-treated diabetic rats, compared with placebo-treated animals.
    1 context sentence
    Summary · context
    Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.